Major Shareholder Files Intent to Sell $727K in Stock Amidst Company's Liquidity Crisis
Summary
A major shareholder, Bayern Capital LLC, has filed to sell $727,600 worth of RetinalGenix Technologies stock, signaling a lack of confidence amidst the company's severe liquidity crisis and going concern warnings.
Key Events
-
Intent to Sell Significant Stake
Steven Bayern for Bayern Capital LLC has filed a Form 144 to sell 181,900 shares of common stock, valued at approximately $727,600. This represents about 0.97% of the company's market capitalization and 0.965% of outstanding shares.
-
Filer is Major Shareholder
The filer, Steven Bayern for Bayern Capital LLC, is identified as a shareholder who previously acquired 4,214,000 shares through warrant exercise.
-
Context of Financial Distress
This intent to sell follows recent disclosures (10-K on 2026-04-15 and 10-Q on 2026-05-20) highlighting RetinalGenix Technologies Inc.'s extreme liquidity crisis, with only $180 in cash as of March 31, 2026, and substantial doubt about its ability to continue as a going concern.
Analysis
A significant shareholder, Bayern Capital LLC, has filed a Form 144 indicating an intent to sell 181,900 shares of RetinalGenix Technologies Inc. common stock, valued at approximately $727,600. This proposed sale, representing nearly 1% of the company's outstanding shares, comes at a critical time, following recent disclosures of an extreme liquidity crisis with only $180 in cash and substantial doubt about the company's ability to continue as a going concern. The intent to sell by a major shareholder in such dire financial circumstances suggests a lack of confidence and could further pressure the stock.
At the time of this filing, RTGN was trading at $4.00 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $75M. The 52-week trading range was $0.25 to $20.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.